Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04467801
Recruitment Status : Recruiting
First Posted : July 13, 2020
Last Update Posted : December 1, 2021
Sponsor:
Collaborators:
University of Iowa
University of Kentucky
Information provided by (Responsible Party):
Jun Zhang, MD, PhD, University of Kansas Medical Center

Brief Summary:

For metastatic/advanced NSCLC patients who do not have targetable mutations, either immunotherapy targeting the programmed death-1 and its ligand (PD-1/L1) pathway alone or in combination with platinum doublet chemotherapy is now a standard of care. However, still about half of the patients do not benefit due to treatment resistance. It is therefore critically important to find novel therapies and combinations to benefit patients who have failed or are intolerant to 1st line immunotherapy.

This study hypothesizes that ipatasertib in combination with taxane (e.g. docetaxel) can be an effective strategy. Ipatasertib is a novel adenosine triphosphate (ATP)-competitive inhibitor that has demonstrated robust and selective targeting of protein kinase B (PKB, also known as AKT) in cancer patients. Importantly, evidence from preclinical studies has demonstrated that AKT inhibitors (e.g. ipatasertib) can enhance the therapeutic effect of chemotherapy as well as immunotherapy via modulating Phosphatidylinositol 3-kinase (PI3'K)-AKT activity.


Condition or disease Intervention/treatment Phase
NSCLC Stage IV NSCLC Stage IIIB Drug: Ipatasertib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center Phase II Study of Ipatasertib in Combination With Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy (Ipat-Lung)
Actual Study Start Date : September 14, 2021
Estimated Primary Completion Date : August 2023
Estimated Study Completion Date : August 2025

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Treatment

Ipatasertib, 400 mg once daily, Oral, Days 1-14 of each 21 day cycle (2 weeks on and 1 week off).

Docetaxel, 75 mg/m2, Intra-venous, Day 1 of each 21 day cycle.

Drug: Ipatasertib
Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.




Primary Outcome Measures :
  1. Progression Free Survival [ Time Frame: up to 12 months ]
    RECIST 1.1


Secondary Outcome Measures :
  1. Number of adverse events experienced by participants receiving treatment with ipatasertib in combination with docetaxel [ Time Frame: At cycle 1day 8 (each cycle is 21 days) up to 2 months (60 days) after End of treatment ]
    CTCAE Version 5.0

  2. Overall Response Rate [ Time Frame: every 6 weeks up to 12 months ]
    RECIST 1.1

  3. Overall Survival [ Time Frame: Cycle 1day 1 (each cycle is 21 days) to up to 12 months after end of treatment ]
    Medical record



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
  • Life expectancy ≥12 weeks
  • Males and females age ≥ 18 years
  • Allowable type and amount of prior therapy:

First line anti-Programmed death receptor and ligand (PD1/PD-L1), either single agent or in combination with chemotherapy

  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
  • Measurable disease per RECIST version 1.1
  • Diagnoses of advanced/metastatic NSCLC and have failed or are intolerant to 1st line anti-PD1/PD-L1, either single agent or in combination with chemotherapy, and have either exhausted or decline or not be candidates for all available standard of care therapies.
  • Adequate organ function
  • Women of child-bearing potential and men with partners of child-bearing potential must agree to practice sexual abstinence, or to use an acceptable form of contraception for the duration of study participation, and for 90 days following completion of therapy
  • Men of child-bearing potential must agree not to donate sperm while on this study and for 90 days after their last study treatment

Exclusion Criteria:

  • Is not concurrent enrolled in another clinical study, unless it is an observational (non-interventional) clinical study or if the participant is in the follow-up period of an interventional study
  • Is not currently on or is not anticipated to use other investigational agents within 14 days prior to and while participating in this study
  • Does not have mixed small cell and non-small cell lung cancer histology
  • Does not have any unresolved toxicity CTCAE >Grade 2 from the prior 1st immunotherapy. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study drug may be included
  • Patients who have targetable mutations that qualify for targeted therapy (e.g. mutations of epidermal growth factor receptor (EGFR), serine/ threonine- protein kinase (BRAF), anaplastic lymphoma kinase (ALK), tyrosine- protein kinase (ROS1), neurotrophic receptor tyrosine kinase (NTRAK)) will be excluded from this study
  • Is not on concomitant therapy intended for the treatment of cancer (including, but not limited to, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, and herbal therapy) for 14 days prior to starting study treatment, depending on the agent and during study treatment, until disease progression is documented and the patient has discontinued study treatment, with the exception of palliative radiotherapy and local therapy per PI discretion
  • Does not chronically use a strong cytochrome P4503A4 (CYP3A4/5) inhibitor or inducer, or sensitive CYP3A substrates with a narrow therapeutic window
  • Has not had recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access) that would prevent administration of study drug
  • Does not have uncontrolled systemic disease
  • Does not have uncontrolled brain metastasis
  • Does not have history of allergy to taxanes
  • Does not have history of leptomeningeal carcinomatosis
  • Does not have recent history of myocardial infarction (MI) or symptomatic coronary artery disease within 6 months of screening
  • Is not receiving active therapy for HIV, hepatitis B or hepatitis C
  • Does not have history of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills
  • Does not have history of Type I or Type II diabetes mellitus requiring insulin (Patients who are on a stable dose of oral diabetes medication greater than or equal to 2 weeks prior to initiation of study treatment
  • Does not have Grade greater than or equal to 2 uncontrolled or untreated hypercholesterolemia or hypertriglyceridemia
  • Does not have history of or active inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)
  • Does not have active pneumonitis
  • Does not have history of lung disease: interstitial lung disease, idiopathic pulmonary fibrosis, cystic fibrosis, Aspergillosis, active tuberculosis, or history of opportunistic infections
  • Does not have uncontrolled pleural effusion/pericardial effusion/or ascites as determined by the investigator
  • Does not have active ventricular arrhythmia requiring medication
  • Does not have psychiatric illness/social situations that would limit compliance with study requirements or compromise the ability of the patient to give written informed consent
  • Is not pregnant, breast feeding or planning to become pregnant while receiving study treatment or for less than 90 days after the last dose of study treatment
  • For males with partners of childbearing potential, is not planning to father a child or donate sperm while receiving study treatment or for less than 90 days after the last dose of study treatment
  • Does not have any condition that, in the opinion of the investigator, would interfere with evaluation or interpretation of patient safety or study results

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04467801


Contacts
Layout table for location contacts
Contact: KUCC Navigator 9135883671 KUCC_Navigation@kumc.edu

Locations
Layout table for location information
United States, Kansas
The University of Kansas Cancer Center (KUCC) Recruiting
Fairway, Kansas, United States, 66205
Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu   
Contact: Steve Williamson, MD    913-588-3808    SWILLIAM@kumc.edu   
The University of Kansas Cancer Center, Westwood Campus Recruiting
Kansas City, Kansas, United States, 66205
Contact: Clinical Trials Nurse Navigator    913-945-7552    ctnursenav@kumc.edu   
The University of Kansas Cancer Center, Overland Park Clinic Active, not recruiting
Overland Park, Kansas, United States, 66210
United States, Missouri
The University of Kansas Cancer Center, North Clinic Active, not recruiting
Kansas City, Missouri, United States, 64154
The University of Kansas Cancer Center, Lee's Summit Clinic Active, not recruiting
Lee's Summit, Missouri, United States, 64064
Sponsors and Collaborators
Jun Zhang, MD, PhD
University of Iowa
University of Kentucky
Investigators
Layout table for investigator information
Principal Investigator: Jun Zhang, MD, PhD The University of Kansas
Layout table for additonal information
Responsible Party: Jun Zhang, MD, PhD, MD, PhD, University of Kansas Medical Center
ClinicalTrials.gov Identifier: NCT04467801    
Other Study ID Numbers: IIT-2019-IpatTax
First Posted: July 13, 2020    Key Record Dates
Last Update Posted: December 1, 2021
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jun Zhang, MD, PhD, University of Kansas Medical Center:
Advanced/metastatic NSCLC
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases